1. Home
  2. SCLX vs FMY Comparison

SCLX vs FMY Comparison

Compare SCLX & FMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • FMY
  • Stock Information
  • Founded
  • SCLX 2011
  • FMY 2005
  • Country
  • SCLX United States
  • FMY United States
  • Employees
  • SCLX N/A
  • FMY N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • FMY Finance/Investors Services
  • Sector
  • SCLX Health Care
  • FMY Finance
  • Exchange
  • SCLX Nasdaq
  • FMY Nasdaq
  • Market Cap
  • SCLX 51.3M
  • FMY 49.6M
  • IPO Year
  • SCLX N/A
  • FMY N/A
  • Fundamental
  • Price
  • SCLX $4.06
  • FMY $12.02
  • Analyst Decision
  • SCLX Strong Buy
  • FMY
  • Analyst Count
  • SCLX 4
  • FMY 0
  • Target Price
  • SCLX $396.67
  • FMY N/A
  • AVG Volume (30 Days)
  • SCLX 103.2K
  • FMY 10.1K
  • Earning Date
  • SCLX 05-12-2025
  • FMY 01-01-0001
  • Dividend Yield
  • SCLX N/A
  • FMY 6.98%
  • EPS Growth
  • SCLX N/A
  • FMY N/A
  • EPS
  • SCLX N/A
  • FMY N/A
  • Revenue
  • SCLX $56,590,000.00
  • FMY N/A
  • Revenue This Year
  • SCLX $115.30
  • FMY N/A
  • Revenue Next Year
  • SCLX $73.33
  • FMY N/A
  • P/E Ratio
  • SCLX N/A
  • FMY N/A
  • Revenue Growth
  • SCLX 21.07
  • FMY N/A
  • 52 Week Low
  • SCLX $5.80
  • FMY $10.71
  • 52 Week High
  • SCLX $80.50
  • FMY $12.17
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 24.27
  • FMY 50.50
  • Support Level
  • SCLX $3.60
  • FMY $11.86
  • Resistance Level
  • SCLX $7.64
  • FMY $11.99
  • Average True Range (ATR)
  • SCLX 1.21
  • FMY 0.14
  • MACD
  • SCLX -0.37
  • FMY 0.00
  • Stochastic Oscillator
  • SCLX 6.67
  • FMY 63.79

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.

Share on Social Networks: